Literature DB >> 11358758

Protecting travellers from hepatitis A.

G Webster, E Barnes, G Dusheiko, I Franklin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11358758      PMCID： PMC1120319          DOI： 10.1136/bmj.322.7296.1194

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  The case for routine childhood vaccination against hepatitis A.

Authors:  R S Koff
Journal:  N Engl J Med       Date:  1999-02-25       Impact factor: 91.245

2.  Transmission of hepatitis A virus infection despite vaccination.

Authors:  B Flehmig; A Normann; D Bohnen
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

3.  Human normal immunoglobulin (HNIG): lack of availability for travellers.

Authors: 
Journal:  Commun Dis Rep CDR Wkly       Date:  2000-08-25

4.  Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial.

Authors:  L Sagliocca; P Amoroso; T Stroffolini; B Adamo; M E Tosti; G Lettieri; C Esposito; S Buonocore; P Pierri; A Mele
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

5.  A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine.

Authors:  B J McMahon; M Beller; J Williams; M Schloss; H Tanttila; L Bulkow
Journal:  Arch Pediatr Adolesc Med       Date:  1996-07

6.  A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team.

Authors:  Y J Hutin; V Pool; E H Cramer; O V Nainan; J Weth; I T Williams; S T Goldstein; K F Gensheimer; B P Bell; C N Shapiro; M J Alter; H S Margolis
Journal:  N Engl J Med       Date:  1999-02-25       Impact factor: 91.245

Review 7.  Risk of hepatitis A in travellers.

Authors:  R Steffen
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

8.  Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees.

Authors:  R H Purcell; E D'Hondt; R Bradbury; S U Emerson; S Govindarajan; L Binn
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

9.  Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers.

Authors:  R H Behrens; J A Roberts
Journal:  BMJ       Date:  1994-10-08

10.  Age-specific antibody prevalence to hepatitis A in England: implications for disease control.

Authors:  N J Gay; P Morgan-Capner; J Wright; C P Farrington; E Miller
Journal:  Epidemiol Infect       Date:  1994-08       Impact factor: 2.451
  10 in total
  3 in total

1.  Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg.

Authors:  J Mossong; L Putz; S Patiny; F Schneider
Journal:  Epidemiol Infect       Date:  2006-01-25       Impact factor: 2.451

2.  Effectiveness of 10-year vaccination (2001-2010) on Hepatitis A in Tianjin, China.

Authors:  Zhi-lun Zhang; Xiang-jun Zhu; Ai-lan Shan; Zhi-gang Gao; Ying Zhang; Ya-xing Ding; Hui Liu; Wei-shen Wu; Yong Liu; Hai-yan He; Xiao-hua Xie; Wei-dong Xia; Chao Li; Wen-ti Xu; Zhi-yuan Li; Hua-liang Lin; Wei-ming Fu
Journal:  Hum Vaccin Immunother       Date:  2014-02-06       Impact factor: 3.452

Review 3.  [Hepatitis as a travel disease].

Authors:  J Hadem; H Wedemeyer; M P Manns
Journal:  Internist (Berl)       Date:  2004-06       Impact factor: 0.743
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.